ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.3 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:1. treatment of moderate to severe vasomotor symptoms associated with menopause. 2. treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metronidazole 250 mg - tablets - metronidazole - for the treatment of : - symptomatic trichomoniasis in women and men when the presence of the trichomonad has been confirmed by appropriate laboratory procedures. - asymptomatic trichomoniasis in women when the organism is associated with endocervicitis cervicitis or cervical erosion. - asymptomatic consort. - acute intestinal amebiasis (amebic dysentery) and amebic liver absess. - anaerobic bacterial infections caused by susceptible anaerobic bacteria.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - losartan potassium 12.5 mg - tablets - losartan - hypertension: ocsaar is indicated for the treatment of hypertension. heart failure: ocsaar is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fosamprenavir as fosamprenavir calcium 700 mg - tablets - fosamprenavir - lexiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults. the following points should be considered when initiating therapy with lexiva/ritonavir in protease inhibitor - experienced patients: - the protease inhibitor - experienced patient study was not large enough to reach a definitive conclusion that lexiva/ritonavir and lopinavir/ritonavir are clinically equivalent. - once - daily administration of lexiva plus ritonvir is not recommended for proteaseinhibitor-experienced patients.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

ישראל - עברית - Ministry of Health

novartis pharma services ag - telbivudine 600 mg - film coated tablets - telbivudine - treatment of chronic hepatitis b in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.the following points should be considered when initiating therapy with sebivo:- for hbeag - positive patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 9log 10 copies/ml and baseline alt>or= 2x uln.- for hbeag - negative patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 7log 10 copies/ml.